Nutra Pharma Finalizes Exclusive Network Marketing Distribution Agreement for Nyloxin
December 02 2013 - 8:00AM
Marketwired
Nutra Pharma Finalizes Exclusive Network Marketing Distribution
Agreement for Nyloxin
Nutra Pharma Is Announcing That MyNyloxin Will Have the
Exclusive Distribution Rights for the Company's Over-the-Counter
(OTC) Pain Reliever, Nyloxin(R) in the Network Marketing
Channel
CORAL SPRINGS, FL--(Marketwired - Dec 2, 2013) - Nutra Pharma
Corp. (OTCQB: NPHC), a biotechnology company that is developing
treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple
Sclerosis (MS), is announcing that MyNyloxin, a new Network
Marketing company, will have the exclusive rights to market and
distribute Nutra Pharma's over-the-counter (OTC) pain reliever,
Nyloxin®, in the Network Marketing channel. Nutra Pharma will
continue to market the products through their retail and Direct
Response distributors.
In September 2012, Nutra Pharma announced the beginning of
distribution efforts by the TCN group of direct distributors. Since
that time, TCN has worked diligently to introduce Nyloxin® to
approximately 40,000 distributors in the United States and almost
400,000 distributors globally. TCN has now created a stand-alone
opportunity for distributors under the name MyNyloxin. The launch
will take place throughout the month of December and will include
webinars, internet, radio and television advertising.
"The Nyloxin products continue to represent a wonderful
opportunity for our distributors," commented Dalton Johnson, CEO of
MyNyloxin. "The new focus of the Company is solely on the Nyloxin
opportunity for our Distributors. These are pain-relievers and
anti-inflammatory drugs that have provided great results with
almost no risk of side effects. With the rollout through the next
several months, our goal is to achieve significant sales through
our distributors that will provide continuity as they use and order
the product every month," he concluded.
Nyloxin® is an over-the-counter (OTC) pain reliever clinically
proven to treat moderate to severe (Stage 2) chronic
pain. Nyloxin® is currently available in the United States as
an oral spray for treating back pain, neck aches, headaches, joint
pain, migraines, and neuralgia, and as a topical gel for treating
joint pain, neck pain, arthritis pain, and pain from repetitive
stress. In addition to its everyday strength formulation, Nyloxin®
is also offered in an extra strength formula for more advanced,
Stage 3, chronic pain. The Company recently announced the beginning
of marketing efforts by New Vitality for the Direct Response and
retail marketing of Nyloxin. New Vitality's first Nyloxin
television commercials are scheduled to begin shortly.
About Nutra Pharma Corp. Nutra Pharma Corporation operates as a
biotechnology company specializing in the acquisition, licensing,
and commercialization of pharmaceutical products and technologies
for the management of neurological disorders, cancer, autoimmune,
and infectious diseases, including Multiple Sclerosis (MS), Human
Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain.
Additionally, the Company markets several drug products for sale
for the treatment of pain under the brands Cobroxin® and Nyloxin®.
For additional information about Nutra Pharma, visit:
http://www.NutraPharma.com or http://www.Nyloxin.com.
SEC Disclaimer This press release contains forward-looking
statements. The words or phrases "would be," "will allow," "intends
to," "will likely result," "are expected to," "will continue," "is
anticipated," "estimate," "project," or similar expressions are
intended to identify "forward-looking statements." Actual results
could differ materially from those projected in Nutra Pharma's
("the Company") business plan. The agreement with MyNyloxin should
not be construed as an indication in any way whatsoever of the
future value of the Company's common stock or its financial value.
The Company's filings may be accessed at the SEC's Edgar system at
www.sec.gov. Statements made herein are as of the date of this
press release and should not be relied upon as of any subsequent
date. The Company cautions readers not to place reliance on such
statements. Unless otherwise required by applicable law, we do not
undertake, and we specifically disclaim any obligation, to update
any forward-looking statements to reflect occurrences,
developments, unanticipated events or circumstances after the date
of such statement.
Nutra Pharma (CE) (USOTC:NPHC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Nutra Pharma (CE) (USOTC:NPHC)
Historical Stock Chart
From Apr 2023 to Apr 2024